

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
SCOPE OF REPORT .....	2
INTENDED AUDIENCE.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	4
RELATED BCC REPORTS .....	4
BCC ON-LINE SERVICES.....	4
DISCLAIMER .....	5
 CHAPTER TWO: SUMMARY.....	 6
SUMMARY.....	6
<i>SUMMARY TABLE MAJOR GENITOURINARY DRUG CATEGORIES</i>	
<i>REVENUE, THROUGH 2016 (\$ MILLIONS)* .....</i>	<i>7</i>
<i>SUMMARY FIGURE MAJOR GENITOURINARY DRUG CATEGORIES</i>	
<i>REVENUE, 2009-2016 (\$ MILLIONS)* .....</i>	<i>8</i>
 CHAPTER THREE: OVERVIEW .....	 9
DISEASES OF THE GENITOURINARY SYSTEM.....	9
<i>TABLE 1 GENITOURINARY DISEASE NAMES, GENDER AND</i>	
<i>DESCRIPTION .....</i>	<i>9</i>
BENIGN PROSTATIC HYPERTROPHY (BPH) .....	9
ERECTILE DYSFUNCTION (ED).....	10
INCONTINENCE (IC) .....	10
OVERACTIVE BLADDER (OB).....	10
HORMONAL CONTRACEPTION (HC).....	11
INFERTILITY (IF).....	11
INFECTION (INF) .....	12
DRUGS GOING OFF-PATENT IN FORECAST PERIOD .....	12
<i>TABLE 2 GENITOURINARY DRUGS WITH EXPIRING PATENTS,</i>	
<i>2010-2016 .....</i>	<i>13</i>
REVENUE PROJECTION FOR GENITOURINARY DRUGS, 2011-	
2016 .....	13
<i>TABLE 3 FIVE-YEAR PROJECTION FOR REVENUES IN</i>	
<i>GENITOURINARY DRUG MARKET, THROUGH 2016 (\$ MILLIONS).....</i>	<i>14</i>
REVENUE PROJECTION FOR ...(CONTINUED).....	15
TOP 10 BEST-SELLING GENITOURINARY DRUGS, 2011.....	16
<i>TABLE 4 TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011</i>	
<i>(\$ MILLIONS/%).....</i>	<i>16</i>
REVENUE BY GENITOURINARY DISEASE DRUG SEGMENT .....	16
<i>TABLE 5 REVENUES BY GENITOURINARY SEGMENT, 2011 (\$</i>	
<i>MILLIONS/%).....</i>	<i>17</i>

REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA.....	17
<i>TABLE 6 REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC AREA, 2011 (\$ MILLIONS/%)</i> .....	17
REVENUE FROM GENITOURINARY...(CONTINUED) .....	18
CHAPTER FOUR: GENITOURINARY DISEASE CONDITIONS .....	19
GENITOURINARY DISEASE CONDITIONS .....	19
BENIGN PROSTATIC HYPERTROPHY .....	20
<i>TABLE 7 MAJOR DRUGS APPROVED FOR TREATMENT OF BENIGN PROSTATIC HYPERTROPHY</i> .....	21
BENIGN PROSTATIC HYPERTROPHY (CONTINUED).....	22
BENIGN PROSTATIC HYPERTROPHY (CONTINUED).....	23
BENIGN PROSTATIC HYPERTROPHY (CONTINUED).....	24
INCONTINENCE AND OVERACTIVE BLADDER .....	25
INCONTINENCE AND OVERACTIVE ... (CONTINUED).....	26
ERECTILE DYSFUNCTION .....	27
<i>TABLE 8 PRESCRIPTION DRUGS THAT HAVE AN ED WARNING</i> .....	28
<i>TABLE 9 CURRENT DRUGS FOR ERECTILE DYSFUNCTION TRATMENT</i> .....	29
INFECTION .....	30
<i>TABLE 10 COMMON BACTERIAL SPECIES IN GENITOURINARY INFECTIONS</i> .....	30
INFERTILITY .....	31
FEMALE INFERTILITY .....	31
Female Infertility (Continued).....	32
MALE INFERTILITY .....	33
Male Infertility (Continued).....	34
HORMONAL CONTRACEPTION .....	35
ORAL CONTRACEPTIVES.....	35
<i>TABLE 11 DESIGN OF HORMONAL CONTRACEPTIVE MEDICATIONS</i> .....	36
<i>TABLE 12 LONG-TERM CONTRACEPTIVE TREATMENTS</i> .....	37
THE MORNING-AFTER PILL.....	37
The Morning-after Pill (Continued) (Continued) .....	38
CHAPTER FIVE MARKET ANALYSIS .....	39
MARKET OVERVIEW .....	39
MARKET OVERVIEW (CONTINUED) .....	40
MARKET SIZE AND FORECAST .....	41
<i>TABLE 13 REVENUE FROM GENITOURINARY DISEASE DRUGS FOR MAJOR COMPANIES, THROUGH 2016 (\$ MILLIONS)</i> .....	41
MARKET SIZE AND FORECAST (CONTINUED).....	42
<i>TABLE 14 FIVE-YEAR PROJECTION FOR REVENUE INCREASES IN GENIROURINARY DRUG MARKET, THROUGH 2016 (\$ MILLIONS)</i> .....	43

CURRENT DRUGS IN THE MARKET .....	44
PIPELINE FORECAST FOR GENITOURINARY DRUGS.....	45
<i>TABLE 15 DRUGS FOR GENITOURINARY DISEASE IN THE</i>	
<i>PIPELINE WORLDWIDE, 2012 .....</i>	<i>45</i>
MARKET BY MECHANISM OF ACTION AND MODE OF DELIVERY .....	45
 CHAPTER SIX: BENIGN PROSTATIC HYPERTROPHY (BPH) .....	 46
OVERVIEW .....	46
ETIOLOGY OF BENIGN PROSTATIC HYPERTROPHY .....	46
ETIOLOGY OF BENIGN PROSTATIC ... (CONTINUED) .....	47
DIAGNOSIS, TREATMENT AND MANAGEMENT .....	48
DRUGS BY MECHANISM OF ACTION .....	49
<i>TABLE 16 MECHANISM OF ACTION OF APPROVED DRUGS FOR</i>	
<i>BPH TREATMENT.....</i>	<i>49</i>
DRUGS BY MECHANISM OF ACTION (CONTINUED).....	50
DRUGS BY MECHANISM OF ACTION (CONTINUED).....	51
D-3263 VERSUS SIPULEUCEL-T:.....	52
PROVENGE (SIPULEUCEL-T) MOA: .....	52
EPIDEMIOLOGY AND STATISTICS DATA .....	52
INCIDENCE OF BPH .....	53
<i>TABLE 17 PERCENTAGE OF MALES (OVER FIFTY) WITH BPH AND</i>	
<i>EXHIBITING SYMPTOMS, 2010 (MILLIONS) .....</i>	<i>54</i>
<i>TABLE 18 PROJECTED INCREASE IN MEN WITH SYMPTOMATIC</i>	
<i>BPH, THROUGH 2016 (MILLIONS).....</i>	<i>54</i>
MANAGEMENT OF BPH .....	55
MECHANISM OF ACTION OF BPH DRUGS .....	55
MECHANISM OF ACTION OF BPH DRUGS (CONTINUED).....	56
<i>TABLE 19 MECHANISM OF ACTION OF APPROVED DRUGS FOR</i>	
<i>BPH TREATMENT.....</i>	<i>57</i>
MARKET ANALYSIS: REVENUES AND FORECAST .....	57
<i>TABLE 20 BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES,</i>	
<i>THROUGH 2016 (\$ MILLIONS).....</i>	<i>58</i>
<i>TABLE 21 REVENUES FROM THE MAJOR BPH DRUGS, THROUGH</i>	
<i>2016 (\$ MILLIONS).....</i>	<i>59</i>
<i>TABLE 22 PROJECTED REVENUES FOR BPH DRUGS BY REGION,</i>	
<i>THROUGH 2016 (\$ MILLIONS).....</i>	<i>59</i>
BPH DRUG SALES BY MECHANISM OF ACTION .....	60
<i>TABLE 23 REVENUE FROM BPH DRUGS BY MECHANISM OF</i>	
<i>ACTION, THROUGH 2016 (\$ MILLIONS).....</i>	<i>60</i>
MAJOR PLAYERS IN BPH MARKET .....	61
<i>TABLE 24 MAJOR PLAYERS IN BPH MARKET IN 2011 (\$ MILLIONS) .....</i>	<i>61</i>
MAJOR BPH DRUG PROFILES.....	61
<i>TABLE 25 PROFILE OF ALPHA-BLOCKER DRUGS.....</i>	<i>62</i>
<i>TABLE 26 PROFILE OF 5-ALPHA-REDUCTASE INHIBITOR DRUGS.....</i>	<i>62</i>

<i>TABLE 27 PROFILE OF DRUGS WITH ALTERNATIVE MECHANISM OF ACTION</i> .....	63
THE PIPELINE FOR BENIGN PROSTATIC HYPERTROPHY	
DRUGS IN PRECLINICAL DEVELOPMENT .....	63
<i>TABLE 28 DRUG FOR BPH PRECLINICAL TRIALS</i> .....	64
<i>TABLE 28 (CONTINUED)</i> .....	65
<i>TABLE 28 (CONTINUED)</i> .....	66
<i>TABLE 28 (CONTINUED)</i> .....	67
<i>TABLE 28 (CONTINUED)</i> .....	68
BPH DRUGS IN PHASE I CLINICAL TRIALS .....	68
<i>TABLE 29 BPH DRUGS IN PHASE I CLINICAL TRIALS</i> .....	69
<i>TABLE 29 (CONTINUED)</i> .....	70
BPH DRUGS IN PHASE II CLINICAL TRIALS .....	71
<i>TABLE 30 DRUGS IN PHASE II CLINICAL TRIALS FOR BPH TREATMENT</i> .....	71
<i>TABLE 30 (CONTINUED)</i> .....	72
DRUGS IN PHASE III CLINICAL TRIALS FOR BPH TREATMENT.....	72
<i>TABLE 31 DRUGS IN PHASE III CLINICAL TRIALS FOR BPH TREATMENT</i> .....	73
<i>TABLE 31 (CONTINUED)</i> .....	72
BPH DRUGS PENDING FDA APPROVAL.....	73
<i>TABLE 32 BPH DRUGS PENDING APPROVAL FROM U.S. FDA</i> .....	74
DRUGS APPROVED BY THE FDA IN 2011.....	75
<i>TABLE 33 FDA APPROVED DRUGS FOR BPH TREATMENT IN 2011</i> .....	75
Drugs Approved by the FDA in 2011 (Continued) .....	76
CHAPTER SEVEN: ERECTILE DYSFUNCTION .....	77
OVERVIEW.....	77
ETIOLOGY OF ERECTILE DYSFUNCTION.....	78
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. DRUGS BY MECHANISM OF ACTION (CONTINUED).....	79
DIAGNOSIS, TREATMENT AND MANAGEMENT .....	79
MECHANISM OF ACTION .....	80
EPIDEMIOLOGICAL AND STATISTICAL DATA.....	80
INCIDENCE OF ERECTILE DYSFUNCTION .....	81
<i>TABLE 34 PROJECTED INCREASE IN ERECTILE DYSFUNCTION, THROUGH 2016 (MILLIONS)</i> .....	81
MECHANISM OF ACTION .....	82
<i>TABLE 35 CURRENT DRUGS FOR ERECTILE DYSFUNCTION TRATMENT</i> .....	82
MARKET ANALYSIS AND FORECAST.....	83
<i>TABLE 36 REVENUES FOR ERECTILE DYSFUNCTION DRUGS, THROUGH 2016 (\$ MILLIONS)</i> .....	83
REGIONAL FORECAST FOR ED REVENUES .....	84

<i>TABLE 37 FORECAST REVENUE INCREASE FROM ERECTILE DYSFUNCTION DRUGS, THROUGH 2016 (\$ MILLIONS)</i> .....	84
<i>TABLE 38 REVENUES AND MARKET SHARE APPROVED ERECTILE DYSFUNCTION DRUGS, 2011 AND 2016 (\$ MILLIONS/%)</i> .....	84
DRUG REVENUES BY MECHANISM OF ACTION .....	85
MAJOR PLAYERS IN THE ERECTILE DYSFUNCTION MARKET .....	85
<i>TABLE 39 MAJOR COMPANIES IN THE ERECTILE DYSFUNCTION DRUG MARKET, 2011 (\$ MILLIONS/%)</i> .....	86
PROFILE OF ERECTILE DYSFUNCTION DRUGS .....	86
<i>TABLE 40 ERECTILE DYSFUNCTION DRUG PROFILES</i> .....	86
ERECTILE DYSFUNCTION DRUG PIPELINE .....	87
DRUGS IN PRECLINICAL DEVELOPMENT STAGE .....	87
<i>TABLE 41 DRUGS IN PRECLINICAL DEVELOPMENT</i> .....	87
Drugs in Preclinical ... (Continued).....	88
DRUGS IN PHASE I CLINICAL TRIALS .....	89
<i>TABLE 42 ERECTILE DYSFUNCTION DRUGS IN PHASE I CLINICAL TRIAL</i> .....	89
DRUGS IN PHASE II CLINICAL TRIALS .....	90
<i>TABLE 43 ERECTILE DYSFUNCTION DRUGS IN PHASE II CLINICAL TRIALS</i> .....	90
<i>TABLE 43 (CONTINUED)</i> .....	91
Drugs in Phase II Clinical Trials (Continued) .....	92
DRUGS IN PHASE III CLINICAL TRIALS .....	93
<i>TABLE 44 ERECTILE DYSFUNCTION DRUGS IN PHASE III CLINICAL TRIALS</i> .....	93
<i>TABLE 44 (CONTINUED)</i> .....	94
ERECTILE DYSFUNCTION DRUGS PENDING FDA APPROVAL .....	95
<i>TABLE 45 ERECTILE DYSFUNCTION DRUGS PENDING FDA APPROVAL</i> .....	95
Erectile Dysfunction Drugs Pending ... (Continued) .....	96
CHAPTER EIGHT: URINARY INCONTINENCE AND OVERACTIVE BLADDER .....	97
OVERVIEW .....	97
STRESS INCONTINENCE .....	98
URGE INCONTINENCE.....	98
OVERFLOW INCONTINENCE .....	98
MIXED INCONTINENCE .....	98
FUNCTIONAL INCONTINENCE .....	99
TOTAL INCONTINENCE .....	99
DIAGNOSIS, TREATMENT AND MANAGEMENT .....	99
<i>TABLE 46 DRUGS FOR TREATMENT OF INCONTINENCE AND OVERACTIVE BLADDER</i> .....	100
DRUG REVENUE BY MECHANISM OF ACTION.....	101

EPIDEMIOLOGY AND STATISTICAL DATA.....	102
INCIDENCE OF INCONTINENCE AND OVERACTIVE BLADDER .....	102
<i>TABLE 47 INCIDENCE OF INCONTINENCE AND OVERACTIVE BLADDER .....</i>	<i>102</i>
MARKET ANALYSIS: SALES AND FORECASTS.....	103
<i>TABLE 48 GLOBAL REVENUES FOR INCONTINENCE AND OVERACTIVE BLADDER DRUGS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>103</i>
THE U.S. MARKET FOR INCONTINENCE AND OVERACTIVE BLADDER DRUGS .....	104
<i>TABLE 49 THE U.S. AND EUROPEAN MARKETS FOR INCONTINENCE/OVERACTIVE BLADDER DRUGS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>104</i>
REVENUE FROM IC/OB DRUGS BY COUNTRY OR REGION.....	105
<i>TABLE 50 REVENUES FROM IC/OB DRUGS BY COUNTRY OR REGION, THROUGH 2016 (\$ MILLIONS) .....</i>	<i>105</i>
MAJOR PLAYERS IN THE INCONTINENCE OVERACTIVE BLADDER DRUG SEGMENT .....	105
<i>TABLE 51 MAJOR PLAYERS IN THE U.S. INCONTINENCE AND OVERACTIVE BLADDER DRUG MARKET BY MARKET SHARE, 2011 (\$ MILLIONS/%).....</i>	<i>105</i>
PROFILE OF THE APPROVED IC/OB DRUGS .....	106
<i>TABLE 52 PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE MARKET .....</i>	<i>106</i>
<i>TABLE 53 PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE MARKET .....</i>	<i>106</i>
COMPANY PIPELINES FOR INCONTINENCE/OVERACTIVE BLADDER DRUGS .....	107
PIPELINE DRUGS FOR IC IN PRECLINICAL DEVELOPMENT PHASE .....	107
<i>TABLE 54 URINARY INCONTINENCE DRUGS IN PRECLINICAL DEVELOPMENT .....</i>	<i>107</i>
<i>TABLE 54 (CONTINUED).....</i>	<i>108</i>
PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS .....	109
<i>TABLE 55 PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS .....</i>	<i>109</i>
PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS.....	109
<i>TABLE 56 PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS.....</i>	<i>110</i>
PIPELINE DRUGS FOR OVERACTIVE BLADDER.....	111
PIPELINE FOR OVERACTIVE BLADDER DRUGS IN PRECLINICAL DEVELOPMENT .....	111
<i>TABLE 57 PIPELINE FOR OVERACTIVE BLADDER DRUGS IN PRECLINICAL DEVELOPMENT .....</i>	<i>111</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>112</i>
PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS.....	113

TABLE 58 PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS.....	113
TABLE 58 (CONTINUED).....	114
PIPELINE FOR OB DRUGS IN PHASE II CLINICAL TRIALS .....	115
TABLE 59 PIPELINE FOR OB DRUGS IN PHASE II CLINICAL TRIALS.....	115
TABLE 59 (CONTINUED).....	116
TABLE 59 (CONTINUED).....	117
PIPELINE FOR OB DRUGS IN PHASE III CLINICAL TRIALS.....	118
TABLE 60 PIPELINE FOR OB DRUGS IN PHASE III TRIALS .....	118
TABLE 60 (CONTINUED).....	119
PIPELINE FOR OB DRUGS IN PENDING FDA APPROVAL.....	120
TABLE 61 PIPELINE FOR OB DRUGS PENDING FDA APPROVAL.....	120
TABLE 61 (CONTINUED).....	121
Pipeline for OB Drugs in ... (Continued).....	122
 CHAPTER NINE: INFERTILITY.....	 123
INFERTILITY OVERVIEW .....	123
DIAGNOSIS, TREATMENT AND MANAGEMENT .....	124
TABLE 62 CAUSES OF INFERTILITY IN WOMEN AND MEN.....	125
FEMALE INFERTILITY .....	125
MALE INFERTILITY .....	126
Male Infertility (Continued).....	127
Male Infertility (Continued).....	128
INFERTILITY DRUGS BY MECHANISM OF ACTION.....	129
TABLE 63 INFERTILITY DRUGS BY MECHANISM OF ACTION .....	129
EPIDEMIOLOGICAL AND STATISTICAL DATA.....	129
INCIDENCE OF INFERTILITY.....	130
TABLE 64 PROJECTED INCIDENCE OF INFERTILITY FOR THE PERIOD, THROUGH 2016.....	131
MARKET ANALYSIS: SALES AND FORECAST.....	131
TABLE 65 REVENUES FROM INFERTILITY DRUGS, THROUGH 2016 (\$ MILLIONS).....	132
SALES BY MECHANISM OF ACTION .....	133
TABLE 66 MECHANISM OF ACTION OF INFERTILITY DRUGS BY 2011 REVENUE (%) .....	133
MAJOR PLAYERS IN THE INFERTILITY MARKET .....	133
TABLE 67 MAJOR PLAYERS IN THE INFERTILITY DRUG MARKET .....	134
INFERTILITY DRUG PROFILES .....	134
TABLE 68 PROFILES OF COMMON INFERTILITY DRUGS .....	135
TABLE 69 PROFILE OF COMMON INFERTILITY DRUGS.....	135
TABLE 70 PROFILE OF COMMON INFERTILITY DRUGS.....	136
PIPELINE FOR INFERTILITY DRUGS.....	136
INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL TRIALS.....	136

<i>TABLE 71 INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL TRIALS.....</i>	<i>137</i>
INFERTILITY DRUGS IN PHASE II OR PHASE III CLINICAL TRIALS.....	137
<i>TABLE 72 INFERTILITY DRUGS IN PHASE II OR PHASE III CLINICAL TRIALS .....</i>	<i>138</i>
MALE INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL TRIALS .....	138
<i>TABLE 73 MALE INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL TRIALS .....</i>	<i>139</i>
Male Infertility Drugs in Phase I... (Continued) .....	140
CHAPTER TEN: HORMONAL CONTRACEPTION .....	141
OVERVIEW.....	141
ETIOLOGY OF HORMONAL CONTRACEPTION .....	141
ORAL CONTRACEPTIVES .....	142
<i>TABLE 74 DOSING SCHEDULES OF HORMONAL CONTRACEPTIVE MEDICATIONS .....</i>	<i>143</i>
<i>TABLE 75 SUMMARY OF LONG-TERM CONTRACEPTIVE TREATMENTS.....</i>	<i>144</i>
THE MORNING-AFTER PILL .....	144
EPIDEMIOLOGY AND STATISTICAL DATA .....	145
INCIDENCE OF HORMONAL CONTRACEPTIVE USE.....	146
<i>TABLE 76 USE OF HORMONAL CONTRACEPTIVE METHODS IN SELECTED COUNTRIES (THOUSANDS).....</i>	<i>146</i>
MARKET ANALYSIS AND FORECAST.....	146
<i>TABLE 77 REVENUES FROM HORMONAL CONTRACEPTION DRUGS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>147</i>
REVENUE FOR HORMONAL CONTRACEPTION BY COUNTRY.....	148
<i>TABLE 78 REVENUE FOR HORMONAL CONTRACEPTION BY COUNTRY/REGION, THROUGH 2016 (\$ MILLIONS).....</i>	<i>148</i>
MAJOR PLAYERS IN HORMONAL CONTRACEPTION DRUGS.....	148
<i>TABLE 79 MAJOR PLAYERS IN THE HORMONAL CONTRACEPTION MARKET .....</i>	<i>148</i>
<i>TABLE 79 (CONTINUED).....</i>	<i>149</i>
<i>TABLE 80 REVENUES OF MAJOR PLAYERS IN THE HORMONAL CONTRACEPTION MARKET, THROUGH 2016 (\$ MILLIONS) .....</i>	<i>149</i>
<i>TABLE 81 PROFILE FOR COMMON DRUGS FOR HORMONAL CONTRACEPTION .....</i>	<i>150</i>
<i>TABLE 82 PROFILE FOR COMMON DRUGS FOR HORMONAL CONTRACEPTION .....</i>	<i>150</i>
PIPELINE FOR HORMONAL CONTRACEPTION DRUGS.....	150
PIPELINE FOR HC DRUGS IN DEVELOPMENT, PHASE I, II CLINICAL TRIALS .....	151



TABLE 83 HC DRUGS IN DEVELOPMENT, PHASE I, II CLINICAL TRIALS.....	151
TABLE 83 (CONTINUED).....	152
PIPELINE FOR HC DRUGS IN PHASE III CLINICAL TRIAL.....	153
TABLE 84 PIPELINE FOR HC DRUGS IN PHASE III CLINICAL TRIALS.....	153
TABLE 84 (CONTINUED).....	154
TABLE 84 (CONTINUED).....	155
PIPELINE FOR HC DRUGS PENDING FDA APPROVAL .....	155
TABLE 85 PIPELINE FOR HC DRUGS PENDING FDA APPROVAL.....	156
Pipeline for HC Drugs Pending FDA approval (Continued)....	157
CHAPTER ELEVEN: GENITOURINARY INFECTION.....	158
OVERVIEW.....	158
TABLE 86 COMMON BACTERIAL SPECIES IN GENITOURINARY INFECTIONS.....	159
MARKET ANALYSIS AND FORECAST.....	160
TABLE 87 TYPICAL BACTERIA CAUSING GENITOURINARY INFECTION AND ANTIBIOTICS FOR THEIR TREATMENT.....	160
MAJOR PLAYERS IN ANTIBIOTICS MARKET .....	161
TABLE 88 GENITOURINARY INFECTIONS AND THE ANTIBIOTICS USED FOR TREATMENT.....	161
CHAPTER TWELVE: GLOBAL GENITOURINARY DISEASE DRUG MARKET .....	162
OVERVIEW.....	162
GLOBAL REVENUES FROM GENITOURINARY DRUGS .....	162
TABLE 89 GLOBAL REVENUES FROM GENITOURINARY DRUGS, THROUGH 2016, (\$ MILLIONS).....	162
GLOBAL INCONTINENCE AND OVERACTIVE BLADDER REVENUE.....	163
TABLE 90 GLOBAL INCONTINENCE AND OVERACTIVE BLADDER REVENUE FORECAST, THROUGH 2016 (\$ MILLIONS).....	163
GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES .....	164
TABLE 91 GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES, THROUGH 2016 (\$ MILLIONS).....	164
GLOBAL REVENUES FROM ERECTILE DYSFUNCTION DRUGS.....	164
TABLE 92 GLOBAL REVENUES FROM ERECTILE DYSFUNCTION DRUGS, THROUGH 2016 (\$ MILLIONS).....	165
GLOBAL REVENUE FROM HORMONAL CONTRACEPTION .....	165
TABLE 93 PROJECTED GLOBAL REVENUE FROM HORMONAL CONTRACEPTION, THROUGH 2016 (\$ MILLIONS).....	165
GLOBAL REVENUE FROM INFERTILITY DRUGS.....	166

<i>TABLE 94 GLOBAL REVENUE FROM INFERTILITY DRUGS, THROUGH 2016 (\$ MILLIONS)</i> .....	166
GENITOURINARY DRUGS ONLY AVAILABLE IN SPECIFIC COUNTRIES.....	167
BENIGN PROSTATIC HYPERTROPHY DRUGS AVAILABLE IN CHINA .....	167
<i>TABLE 95 BPH DRUGS ONLY AVAILABLE IN CHINA</i> .....	167
ERECTILE DYSFUNCTION DRUGS AVAILABLE IN INDIA .....	167
<i>TABLE 96 ERECTILE DYSFUNCTION DRUGS AVAILABLE ONLY IN INDIA</i> .....	168

CHAPTER THIRTEEN: PATENT EXAMPLES FOR GENITOURINARY DRUGS .....	169
<i>TABLE 97 U.S. PATENTS FOR GENITOURINARY DRUGS</i> .....	169
<i>TABLE 97 (CONTINUED)</i> .....	170

CHAPTER FOURTEEN: COMPANY PROFILES .....	171
AGILE THERAPEUTICS.....	171
PRODUCTS .....	171
STRATEGY.....	172
ALLERGAN INC.....	172
PRODUCTS .....	172
STRATGEY.....	173
ANTARES PHARMA INC.....	173
PRODUCTS .....	173
STRATEGY.....	174
ASTELLAS PHARMACEUTICALS US INC.....	174
PRODUCTS .....	174
STRATEGY.....	175
BAYER HEALTHCARE PHARMACEUTICALS .....	175
PRODUCTS .....	176
STRATEGY.....	176
BOEHRINGER-INGELHEIM GMBH .....	176
PRODUCTS .....	177
STRATEGY.....	177
DONG-A PHARMACEUTICAL CO. LTD.....	177
PRODUCTS .....	178
STRATEGY.....	178
ELI LILLY COMPANY .....	178
PRODUCTS .....	179
STRATEGY.....	179
ENDO LABORATORIES.....	179
PRODUCTS .....	179
STRATEGY.....	180
FERRING PHARMACEUTICALS S.A. ....	180

PRODUCTS .....	181
STRATEGY .....	181
GLAXOSMITHKLINE .....	181
PRODUCTS .....	182
STRATEGY .....	182
KISSEI PHARMACEUTICAL CO. LTD. ....	183
PRODUCTS .....	183
MERCK & CO. ....	183
PRODUCTS .....	184
<i>TABLE 98 MERCK &amp; CO, GENITOURINARY DRUG PRODUCTS.....</i>	<i>184</i>
STRATEGY .....	184
MERCK SERONO S.A. ....	185
PRODUCTS .....	185
STRATEGY .....	186
NOVARTIS INTERNATIONAL AG .....	186
PRODUCTS .....	187
<i>TABLE 99 WOMEN'S HEALTH PRODUCTS FROM NOVARTIS.....</i>	<i>187</i>
STRATEGY .....	188
NYMOX PHARMACEUTICAL CORPORATION.....	188
PRODUCTS .....	188
PFIZER CORPORATION .....	189
PRODUCTS .....	189
STRATEGY .....	190
PREGLEM S.A. ....	190
PRODUCTS .....	191
STRATEGY .....	191
RECORDATI S.P.A. ....	192
PRODUCTS .....	192
ROTTAPHARM SPA.....	192
PRODUCTS .....	193
TEVA PHARMACEUTICALS INDUSTRIES LTD. ....	193
PRODUCTS .....	194
STRATEGY .....	194
VIVUS PHARMACEUTICALS INC.....	194
PRODUCTS .....	195
STRATEGY .....	195
WARNER-CHILCOTT PLC.....	195
PRODUCTS .....	196
<i>TABLE 100 WARNER CHILCOTT PRODUCTS FOR WOMEN'S</i>	
<i>HEALTH.....</i>	<i>196</i>
STRATEGY .....	197
WATSON PHARMACEUTICALS .....	197
PRODUCTS .....	197
STRATEGY .....	198